Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Data from intralesional trial in mycosis fungoides/Sézary syndrome patients continue to show promise, with rapid reductions in CAILS scores in the majority of patients and preliminary evidence of...
-
TORONTO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
-
Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target ConferenceUpdated data from the TTI-621 intralesional trial in patients with mycosis...
-
TORONTO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
-
Increased focus on T cell lymphoma in lead program, TTI-621 Initiated dosing of TTI-622 (SIRPaFc IgG4) in phase 1a/1b clinical trial Recruited Dr. Yaping Shou as Chief Medical OfficerNegotiated...
-
Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement
TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) (“Trillium” or the “Company”), a clinical stage immuno-oncology company developing innovative therapies...
-
TORONTO, June 15, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
-
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
-
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
-
TORONTO, June 05, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...